NDLI: Search for approaches to correction of daytime sleepiness induced by dopaminergic drugs during treatment of Parkinson’s disease: Neurochemical aspects

Please wait, while we are loading the content...

Changes in expression and activity of CD38 in astroglial cells after impairment of the neuron-glia relationship in the brain induced by perinatal hypoxia-ischemia

Proteinase inhibitors in the cerebrospinal fluid in neurological diseases

Search for approaches to correction of daytime sleepiness induced by dopaminergic drugs during treatment of Parkinson’s disease: Neurochemical aspects

Neurochemical Journal : Volume 3, Issue 2, June 2009

Neurochemical Journal : Volume 3, Issue 1, March 2009

Neurochemical Journal : Volume 2

Neurochemical Journal : Volume 1

Search for approaches to correction of daytime sleepiness induced by dopaminergic drugs during treatment of Parkinson’s disease: Neurochemical aspects

Content Provider	Springer Nature Link
Author	Silkis, I. G.
Copyright Year	2009
Abstract	We proposed an approach to searching for a new drug that suppress increased daytime sleepiness induced by dopaminergic drugs during treatment of Parkinson’s disease. The search is based on the results of analysis of the effects of neuromodulators (dopamine, adenosine, and acetylcholine) on the mutually dependent functioning of the neuronal circuit motor cortex-basal ganglia-thalamus-motor cortex, which is involved in motor activity, and neural networks that regulate the sleep-wakefulness cycle and contain histaminergic cells of tuberomammillary nucleus and cells of the lateral hypothalamus, which express hypocretin/orexin and melanin- concentrating hormone (MCH). We used the unified rules of modulation of synaptic transmission, which we previously proposed. Our analysis suggests that to suppress increased daytime sleepiness it is necessary to decrease the dose of dopaminergic drugs and use drugs that contain antagonists of adenosine A1 and A2A receptors (for example, caffeine). These antagonists have an antiparkinsonian effect because they, like dopamine, can modulate corticostriatal outputs and, hencethus, facilitate motor activity. In contrast to dopaminergic drugs, they do not cause dyskinesia and cognitive disorders. Antagonists of A1 and A2A receptors also have anti-somnolent effect because they decrease MCH concentration and prevent the depressing action of endogenous adenosine on the activitiesy of cells that release orexin and histamine. Maintenance of high concentrations of orexin and histamine should promote wakefulness.
Starting Page	221
Ending Page	231
Page Count	11
File Format	PDF
ISSN	18197124
Journal	Neurochemical Journal
Volume Number	3
Issue Number	3
e-ISSN	18197132
Language	English
Publisher	SP MAIK Nauka/Interperiodica
Publisher Date	2009-09-19
Publisher Place	Dordrecht
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Parkinson’s disease daytime sleepiness dopamine adenosine hypocretin/orexin histamine synaptic plasticity Neurosciences
Content Type	Text
Resource Type	Article
Subject	Molecular Biology Biochemistry Cellular and Molecular Neuroscience

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

LETTER TO THE EDITOR Parkinson’s disease, sleepiness and hypocretin/orexin

LETTER TO THE EDITOR Parkinson’s disease, sleepiness and hypocretin/orexin (2007)

Adenosine A$_{2A}$ receptors in Parkinson’s disease treatment

The neurochemistry of the sleep-wakefulness cycle and Parkinson’s disease

The state of the tuberoinfundibular dopaminergic system during modeling of parkinsonism in mice

Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson’s disease

Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment

Dopamine Selectively Sensitizes Dopaminergic Neurons to Rotenone-Induced Apoptosis

Histamine impairs midbrain dopaminergic development in vivo by activating histamine type 1 receptors

Search for approaches to correction of daytime sleepiness induced by dopaminergic drugs during treatment of Parkinson’s disease: Neurochemical aspects

Similar Documents

LETTER TO THE EDITOR Parkinson’s disease, sleepiness and hypocretin/orexin

LETTER TO THE EDITOR Parkinson’s disease, sleepiness and hypocretin/orexin (2007)

Adenosine A$_{2A}$ receptors in Parkinson’s disease treatment

The neurochemistry of the sleep-wakefulness cycle and Parkinson’s disease

The state of the tuberoinfundibular dopaminergic system during modeling of parkinsonism in mice

Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson’s disease

Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment

Dopamine Selectively Sensitizes Dopaminergic Neurons to Rotenone-Induced Apoptosis

Histamine impairs midbrain dopaminergic development in vivo by activating histamine type 1 receptors

Search for approaches to correction of daytime sleepiness induced by dopaminergic drugs during treatment of Parkinson’s disease: Neurochemical aspects